FinnCap restated their corporate rating on shares of Avacta Group Plc (LON:AVCT) in a research note published on Thursday morning. FinnCap currently has a GBX 200 ($2.60) price target on the biotechnology company’s stock.

Avacta Group Plc (AVCT) opened at 75.50 on Thursday. The stock’s market cap is GBX 51.63 million. Avacta Group Plc has a one year low of GBX 60.00 and a one year high of GBX 103.95. The firm’s 50 day moving average price is GBX 81.20 and its 200 day moving average price is GBX 78.93.

TRADEMARK VIOLATION NOTICE: This news story was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this news story on another website, it was stolen and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this news story can be read at

In other news, insider Alastair Smith bought 33,225 shares of the company’s stock in a transaction that occurred on Monday, August 21st. The stock was acquired at an average price of GBX 75 ($0.97) per share, for a total transaction of £24,918.75 ($32,349.41). Also, insider Michael Scott Albin bought 4,345 shares of the company’s stock in a transaction that occurred on Tuesday, July 4th. The shares were purchased at an average price of GBX 86 ($1.12) per share, with a total value of £3,736.70 ($4,850.97).

About Avacta Group Plc

Avacta Group plc is a biotechnology company. Avacta’s focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development. Affimer technology has been designed to address performance limitations of antibodies.

Receive News & Ratings for Avacta Group Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avacta Group Plc and related companies with Analyst Ratings Network's FREE daily email newsletter.